Higher dose of abemaciclib for early high-risk breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests whether a higher dose of abemaciclib (a pill that helps stop cancer cells from growing) is safe and effective when used after surgery for early high-risk breast cancer. It is for people whose cancer is hormone receptor positive and HER2 negative, and who will take it along with endocrine therapy (hormone-blocking treatment).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- Your breast cancer is hormone receptor positive (ER or PR positive) and HER2 negative.
- You have completed surgery to remove the cancer (mastectomy or lumpectomy).
- You are planning to take abemaciclib plus hormonal therapy for at least 12 weeks.
- You have not taken any CDK4/6 inhibitor (like palbociclib, ribociclib, or abemaciclib) before.
- You have no serious digestive problems like chronic diarrhea or inflammatory bowel disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether women with early-stage HR+/HER2- breast cancer can safely take a higher dose of the drug abemaciclib (Verzenio) after surgery. The goal is to keep the treatment as strong as possible while managing side effects.
This trial tests whether adding a targeted therapy (abemaciclib) to standard chemotherapy before surgery can shrink tumors and improve outcomes in hormone-positive, HER2-negative early breast cancer. It also uses a genetic test (Oncotype DX) to help guide surgical choices.
This trial tests a drug called abemaciclib for people with early-stage, hormone-receptor-positive, HER2-negative breast cancer who still have cancer DNA in their blood after completing standard treatment. It aims to see if taking this drug can reduce the chance of cancer coming back.
This study follows women taking abemaciclib (a targeted cancer drug) for early-stage hormone-receptor-positive breast cancer to understand how the treatment affects their quality of life and health outcomes. The goal is to improve care for people in this situation.
This study looks at how the body handles the drug abemaciclib, and how it relates to severe diarrhea, which is a common side effect. It is for people with high-risk, hormone receptor positive breast cancer who have already had surgery. The goal is to better understand and possibly manage diarrhea, so you can stay on treatment.
This Phase 2 study tests whether abemaciclib combined with standard hormone (endocrine) therapy can better control metastatic breast cancer in people age 70 and older. It may help if your cancer has already grown despite prior hormone therapy and/or other cancer medicines.
Hear when a new HR+/HER2- Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.